MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
MAIA Biotechnology, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 61.74M shares outstanding
USMAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer.
The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Leadership
Cristian Luput
Director
Jean-Manassé Theagène
Director
Jeffrey C. Himmelreich
Head of Finance and Principal Financial & Accounting Officer
Louie Ngar Yee
Director
Employees
13
Country
US
Sector
Healthcare
Website
maiabiotech.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Smith Stan | Director | Grant/Award | 38.9K | -- | Sep 30, 2026 |
 Theagene Jean-Manasse | Director | Grant/Award | 32.0K | -- | Sep 30, 2026 |
 CHAOUKI STEVEN M | Director | Grant/Award | 32.8K | -- | Sep 30, 2026 |
 Guerrero Ramiro | Director | Grant/Award | 32.0K | -- | Sep 30, 2026 |
 Louie Ngar Yee | Director | Grant/Award | 39.6K | -- | Sep 30, 2026 |
 Luput Cristian | Director | Grant/Award | 33.5K | -- | Sep 30, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Vlad Vitoc · may incl. warrants· filed Dec 2025 | 3.8M | 6.2% | 13D |
Solas Capital Management, LLC | 3.0M | 4.9% | 13F |
FGMK Business Holdings, LLC · may incl. warrants· filed Mar 2025 | 2.9M | 4.7% | 13G |
Alyeska Investment Group, L.P. | 2.5M | 4.0% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | 3.9% | 13F |
Louie Ngar Yee 2 · may incl. warrants· stale · filed Oct 2024 | 1.6M | 2.6% | 13D |
The Stan V. Smith Trust Dated 1993 2 · may incl. warrants· stale · filed Oct 2024 | 1.5M | 2.5% | 13D |
Sergei M. Gryaznov · filed Feb 2025 | 44.5K+1.1M via options | 1.8% | 13G |
683 Capital Management, LLC | 1.1M | 1.7% | 13F |
Centric Wealth Management | 796.7K | 1.3% | 13F |
Insiders
- Smith StanDirector
- Theagene Jean-ManasseDirector
- CHAOUKI STEVEN MDirector
- Guerrero RamiroDirector
- Louie Ngar YeeDirector
- Luput CristianDirector
- Vitoc VladChief Executive Officer
- Gryaznov SergeiChief Scientific Officer
- Himmelreich Jeffrey CHead of Finance
based on 61.74M shares outstanding
US30d Avg
442.92K
60d Avg
528.92K
90d Avg
473.09K